Marché mondial du syndrome de Fanconi-Bickel – Tendances et prévisions de l'industrie jusqu'en 2029

Analyse et perspectives du marché mondial du syndrome de Fanconi-Bickel

Le marché du syndrome de Fanconi-Bickel devrait connaître une croissance de 4,00 % au cours de la période de prévision de 2022 à 2029 et devrait atteindre la valeur de 5 553,96 millions USD d'ici 2029. Le rapport de Data Bridge Market Research sur le marché du syndrome de Fanconi-Bickel fournit une analyse et des informations sur les différents facteurs qui devraient prévaloir tout au long de la période de prévision tout en fournissant leurs impacts sur la croissance du marché. L'essor du secteur de la santé à l'échelle mondiale accélère la croissance du marché du syndrome de Fanconi-Bickel.

Le syndrome de Fanconi-Bickel est un type rare de maladie de stockage du glycogène (MSG). Le syndrome est généralement causé par des mutations homozygotes ou hétérozygotes composées du gène GLUT2. Le GLUT2 est considéré comme le transporteur de glucose facilitateur le plus important dans les cellules bêta pancréatiques, les cellules tubulaires rénales, les hépatocytes et les entérocytes. Environ 112 patients ont été enregistrés comme souffrant du syndrome de Fanconi-Bickel.

L'augmentation du nombre de personnes souffrant du syndrome de Fanconi-Bickel à travers le monde est l'un des principaux facteurs de croissance du marché du syndrome de Fanconi-Bickel. L'augmentation de la demande de médicaments spécifiques pour traiter les symptômes, notamment l'hépatomégalie secondaire à l'hypoglycémie à jeun, l'accumulation de glycogène, l'intolérance au glucose et au galactose, entre autres, accélère la croissance du marché. L'augmentation du nombre d'essais cliniques pour l'amélioration des médicaments et l'accent mis sur la recherche et le développement pour améliorer les thérapies existantes pour les troubles génétiques rares influencent davantage le marché. En outre, les activités de recherche et développement, l'amélioration des soins de santé, l'augmentation des dépenses de santé et la sensibilisation accrue aux troubles génétiques au sein de la population ont un impact positif sur le marché du syndrome de Fanconi-Bickel. En outre, le développement de médicaments et de thérapies spécifiques offre des opportunités rentables aux acteurs du marché au cours de la période de prévision de 2022 à 2029.

On the other hand, high cost associated with the treatment and lack of diagnosis are expected to obstruct the market growth. Lack of skilled professionals is projected to challenge the fanconi-bickel syndrome market in the forecast period of 2022-2029.

This fanconi-bickel syndrome market report provides details of new recent developments, trade regulations, import export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info fanconi-bickel syndrome market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth. 

Global Fanconi-Bickel Syndrome Market Scope and Market Size

The fanconi-bickel syndrome market is segmented on the basis of drug classification, indication, distribution channel and end-users. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.

• On the basis of drug classification, the fanconi-bickel syndrome market is segmented into meglitinides, biguanides, thiazolidinediones, calcitriol, epoetin beta, methoxy polyethylene glycol and others.
• On the basis of indication, the fanconi-bickel syndrome market is segmented into glucose homeostasis, renal losses and others.
• On the basis of distribution channel, the fanconi-bickel syndrome market is segmented into hospital pharmacy, retail pharmacy and online pharmacy.
• On the basis of end-users, the fanconi-bickel syndrome market is segmented into hospitals, homecare, specialty clinics and others.

Fanconi-Bickel Syndrome Market Country Level Analysis

The transthyretin amyloid cardiomyopathy treatment market is analyzed and market size information is provided by country, drug classification, indication, distribution channel and end-users as referenced above.

The countries covered in the global fanconi-bickel syndrome market report are U.S., Canada and Mexico in North America, Peru, Brazil, Argentina and Rest of South America as part of South America, Germany, Italy, U.K., France, Spain, Netherlands, Belgium, Switzerland, Turkey, Russia, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe in Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific (APAC) in Asia-Pacific (APAC), South Africa, Saudi Arabia, U.A.E, Kuwait, Israel, Egypt, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA).

North America dominates the fanconi-bickel syndrome market due to the presence of developed healthcare infrastructure within the region. Asia-Pacific is expected to witness high growth during the forecast period of 2022 to 2029 because of the increase in the research and development activities in the region.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, disease epidemiology and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.

Patient Epidemiology Analysis

The fanconi-bickel syndrome market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analysis of epidemiology to market growth are analyzed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.

Competitive Landscape and Fanconi-Bickel Syndrome Market Share Analysis

The fanconi-bickel syndrome market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies’ focus related fanconi-bickel syndrome market.

Français Certains des principaux acteurs opérant sur le marché du syndrome de Fanconi-Bickel sont F. Hoffmann-La Roche Ltd., Novartis AG, Pfizer Inc., AbbVie Inc., AstraZeneca, Baxter, Eli Lilly and Company, Johnson & Johnson Services Inc., Merck KGaA, Novo Nordisk A/S, Bristol-Myers Squibb Company, Alexion Pharmaceuticals, Inc., Kyowa Hakko Kirin Co., Ltd., Amgen Inc., Biogen, Celldex Therapeutics, GlaxoSmithKline plc., Eisai Co., Ltd., Takeda Pharmaceutical Company Limited et Vertex Pharmaceuticals Incorporated, entre autres.

SKU-67520